IBTV

🎥 “Everything starts with a drop of blood or a cell, and our equipment is the foundation of all that work.” In her recent interview with IBTV, our CEO, Antoinette Gawin, shares why #diversity is so essential to advancing healthcare. From understanding patient needs to clinical trials, leadership and the role of AI, Antoinette explains how bringing diverse voices to the table helps us create better solutions for everyone. “We have a moral and ethical obligation to challenge assumptions and ensure tomorrow’s solutions serve everyone.” 👉 Watch the video to hear more from Antoinette, and let us know: What steps are you taking in your organization to embrace diversity? https://lnkd.in/gbc8KZre #Patientimpact #Leadership #DEI

🩸 "The need for blood never goes away..." 📹 In this Movers & Shakers interview, Chetan Makam (Terumo Blood and Cell Technologies) talks to IBTV about the universal challenge of access to blood, considering the value of the perishable resource and how to maximise each donation. As an essential medicine, the components of blood are needed for a wide range of treatments and disease states - addressing challenges surrounding access to blood is more urgent than ever. #Blood #BloodAsAnEssentialMedicine #BloodDonation #SickleCell AABB

🎥 “Everything starts with a drop of blood or a cell, and our equipment is the foundation of all that work.” In her recent interview with IBTV, our CEO, Antoinette Gawin, shares why #diversity is so essential to advancing healthcare. From understanding patient needs to clinical trials, leadership and the role of AI, Antoinette explains how bringing diverse voices to the table helps us create better solutions for everyone. “We have a moral and ethical obligation to challenge assumptions and ensure tomorrow’s solutions serve everyone.” 👉 Watch the video to hear more from Antoinette, and let us know: What steps are you taking in your organization to embrace diversity? https://lnkd.in/gbc8KZre #Patientimpact #Leadership #DEI

🩺 Alexander Seyf (Autolomous) speaks to IBTV about equitable patient access, the importance of having the patient at the center of therapeutic development, and about how Autolomous is utilizing software in order to empower patient-centric programs. ▶️ Watch the full interview below, or catch up on all the insights from Mesa, here: https://lnkd.in/eF-SM8pq #CGT #CellTherapy #GeneTherapy #AdvancedTherapies #CGMesa24 #PatientAccess #PatientCentricity

💸 We're putting the Spotlight on funding and finance this Friday... It's no secret that investment and financing are challenging subject areas within the cell and gene therapy industry at the moment, often met with a cautious approach to the conversation. However, this field is also ripe with innovation and ideas to address some of these key issues. At Meeting on the Mesa this year, IBTV spoke to a pool of experts about their perspectives on the current investment landscape, collating these insights into our first Spotlight collaborative interview, focussing on CGT investment. ▶ Watch the full interview, here: https://lnkd.in/e8rt79kG George Eastwood from the Emily Whitehead Foundation gets us started, but watch the full video to also hear from: 🎤 Priya Baraniak, Ph.D. 🎤 Miguel Forte, ISCT, International Society for Cell & Gene Therapy & Kiji Therapeutics 🎤 Stella K. Vnook, Likarda 🎤 Alexander Seyf, Autolomous 🎤 Steve Becker, Broken String Biosciences 🎤 Mary Schaheen, Prevail Partners LLC 🎤 Jason Jones, Cellular Origins 🎤 John Keach, RoslinCT 🎤 Raphaël G. Ognar, MSc MBA, NKILT Therapeutics, Inc. 🎤 Delara Motlagh, Catalent Pharma Solutions 🎤 Becky Cap, Vitalant 🎤 Jason C. Foster, Ori Biotech Alliance for Regenerative Medicine #CGMesa24 #CellTherapy #GeneTherapy #Investment #AdvancedTherapies

📹 In this Movers & Shakers interview from Meeting on the Mesa, Jason C. Foster (Ori Biotech) introduces the CGT manufacturing technology company, before exploring the challenges associated with the circular supply chain associated with autologous therapies. 💰 Jason goes on to discuss what's needed to bring investment back to the cell and gene therapy space, summarizing some key takeaways from the meeting. ▶ Want to see more? Catch up with many more insights from the show floor, here: https://lnkd.in/eF-SM8pq

Jeff Wren, VP of Biotherapies at AABB, summarizes his key takeaways from the AABB Annual Meeting, including: 🧬 Commercializing new allogeneic cell therapy products. 🤖 The use of AI in the GMP setting. 🩸 The use of emerging technologies in addressing supply chain challenges. ▶ Hear more about the key takeaways from AABB from more of the experts, here: https://lnkd.in/edkPYdep

🖥 In today's dose from AABB's annual meeting, Philip Garrott introduces JTG Consulting Group to IBTV, providing a brief overview of the importance of addressing IT solutions within the laboratory. ▶ Catch up on all our expert insights from AABB, here: https://lnkd.in/edkPYdep #AABB #AABB24 #IT #ITSolutions

🩸 From the AABB Annual Meeting's show floor, Terumo Blood and Cell Technologies' Chetan Makam introduces the Reveos® Automated Blood Processing System to IBTV as a disruptive technology, explaining how this technology contributes to addressing the platelet shortage. Chetan goes on to discuss further challenges associated with blood processing, including operational efficiencies, donor issues as well as attracting and retaining the right talent. ▶ Watch the full Movers & Shakers series from AABB, here: https://lnkd.in/edkPYdep #AABB #AABB24 #BloodIsAnEssentialMedicine #ImportanceOfBlood #BloodProcessing #BloodDonation

💸 We're putting the Spotlight on funding and finance this Friday... It's no secret that investment and financing are challenging subject areas within the cell and gene therapy industry at the moment, often met with a cautious approach to the conversation. However, this field is also ripe with innovation and ideas to address some of these key issues. At Meeting on the Mesa this year, IBTV spoke to a pool of experts about their perspectives on the current investment landscape, collating these insights into our first Spotlight collaborative interview, focussing on CGT investment. ▶ Watch the full interview, here: https://lnkd.in/e8rt79kG George Eastwood from the Emily Whitehead Foundation gets us started, but watch the full video to also hear from: 🎤 Priya Baraniak, Ph.D. 🎤 Miguel Forte, ISCT, International Society for Cell & Gene Therapy & Kiji Therapeutics 🎤 Stella K. Vnook, Likarda 🎤 Alexander Seyf, Autolomous 🎤 Steve Becker, Broken String Biosciences 🎤 Mary Schaheen, Prevail Partners LLC 🎤 Jason Jones, Cellular Origins 🎤 John Keach, RoslinCT 🎤 Raphaël G. Ognar, MSc MBA, NKILT Therapeutics, Inc. 🎤 Delara Motlagh, Catalent Pharma Solutions 🎤 Becky Cap, Vitalant 🎤 Jason C. Foster, Ori Biotech Alliance for Regenerative Medicine #CGMesa24 #CellTherapy #GeneTherapy #Investment #AdvancedTherapies